CoChat

Biomass specific perfusion rate as a control lever for the continuous manufacturing of biosimilar monoclonal antibodies from CHO cell cultures

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 9 of the 32 sources its claims cite were checked for support.

Abstract

Continuous manufacturing enables high volumetric productivities of biologics such as monoclonal antibodies. However, it is challenging to maintain both high viable cell densities and productivities at the same time for long culture durations. One of the key controls in a perfusion process is the perfusion rate which determines the nutrient availability and potentially controls the cell metabolism. Cell Specific Perfusion Rate (CSPR) is a feed rate proportional to the viable cell density while Biomass Specific Perfusion Rate (BSPR) is a feed rate proportional to the biomass (cell volume multiply by cell density). In this study, perfusion cultures were run at three BSPRs in the production phase. Low BSPR favored a growth arresting state that led to gradual increase in cell volume, which in turn led to an increase in net perfusion rate proportional to the increase in cell volume. Consequently, at low BSPR, while the cell viability and cell density decreased, high specific productivity of 55 pg per cell per day was achieved. In contrast, the specific productivity was lower in bioreactors operating at a high BSPR. The ability to modulate the cell metabolism by using BSPR was confirmed when the specific productivity increased after lowering the BSPR in one of the bioreactors that was initially operating at a high BSPR. This study demonstrated that BSPR significantly influenced cell growth, metabolism, and productivity in cultures with variable cell volumes.

Overview

CoChat Summary

TL;DR

Biomass specific perfusion rate (BSPR) was tested as a control lever in CHO perfusion cultures producing an omalizumab biosimilar, with low BSPR triggering growth arrest, larger cells, and higher specific productivity. The study concludes that BSPR can modulate cell growth, metabolism, and productivity by accounting for increasing cell volume during production.

Key findings

  • Low BSPR (6.5 mL cm⁻³ per day) reduced growth and viability but increased cell diameter from 16.5 µm to 21.7 µm (31.5% increase) by Day 14, while specific productivity reached 55.7 pg cell⁻¹ day⁻¹, three times that at BSPR 12 mL cm⁻³ per day; permeate titer was 2.97 times higher, volumetric productivity 2.5 times higher, and total product mass 1.7 times greater than at BSPR 12.
  • Higher BSPR increased lactate and decreased ammonium: final lactate was 0.35 ± 0.09, 0.55 ± 0.07, and 0.73 ± 0.01 g L⁻¹ for BSPR 6.5, 8.0, and 12 mL cm⁻³ per day, respectively; final ammonium was 8.91 ± 0.68, 5.68 ± 0.05, and 4.52 ± 0.18 mM, respectively.
  • Lowering BSPR from 12 to 6.5 mL cm⁻³ per day on Day 14 caused a response within 48 h: growth rate dropped from 0.18 to 0.04 per day, cell diameter increased significantly to 19.5 µm (p = 0.038), and Qp was 23.2 ± 3.5 versus 17.6 ± 0.6 pg cell⁻¹ day⁻¹ for unchanged BSPR 12; biomass-specific productivity was not significantly different (7.7 ± 1.0 versus 6.3 ± 0.4 pg cm⁻³ day⁻¹).
  • Increasing glucose setpoint from 3 to 6 g L⁻¹ did not significantly improve viable cell density or viability, but increased lactate from 0.32 ± 0.04 to 0.44 ± 0.07 g L⁻¹ and decreased ammonium from 8.9 ± 0.6 to 7.3 ± 0.3 mM.

Methods

  • Suspension CHO cells expressing an omalizumab biosimilar were run in parallel Ambr 250 high-throughput perfusion bioreactors at 223 mL working volume, with duplicates and hollow fiber TFF filters; temperature was shifted from 37°C to 34°C when viable cell density exceeded 50 million cells mL⁻¹, and automated bolus bleeding maintained density below 60 million cells mL⁻¹.
  • Growth phase used CSPR 0.125 nL cell⁻¹ day⁻¹ up to 2 VVD; production phase used BSPR 6.5, 8.0, or 12 mL cm⁻³ per day. On Days 14 and 20, either glucose setpoint or BSPR was changed in one bioreactor per duplicate set.
  • At-line measurements used Bioprofile FLEX2 for cell density, viability, diameter, glucose, lactate, and ammonium; amino acids were measured by UPLC; product quality used Protein A HPLC, SEC, cation exchange, and CE-SDS. Productivity was calculated from product in bioreactor, bleed, and permeate divided by average cell number; two-factor ANOVA with Tukey’s HSD used p < 0.05.

Limitations

  • The paper states that reducing ammonium production by supplementing media with lactate or pyruvate was not tested in this study.
  • The paper reports n = 1 for the BSPR shift experiment (12 to 6.5 mL cm⁻³ per day) and for the glucose shift experiment (3 to 6 g L⁻¹), limiting statistical strength for those interventions.
  • Evident from the text: experiments were performed in 250 mL Ambr 250 mini bioreactors, so scale-up to larger manufacturing bioreactors was not demonstrated; product quality was sampled only on Days 8 and 14.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/biot.202400092

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

8 Valid · 3 Not valid · 15 Not checked · 92 Own results and interpretations

57 more claims

Create a free account to see all 118 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 26
  • It may state two separate claims as one. 37

Create a free account to see these claims.

Citations

Cites

Show all 32 references

Cited by

Metadata

Authors
Leong, J., Tang, W. Q., Chng, J., Ler, W. X., Manan, N. A., Sim, L. C., Zheng, Z. Y., Zhang, W., Walsh, I., Zijlstra, G., Pennings, M., & Ng, S. K.
Affiliations
  • Agency for Science, Technology and Research (SG)
  • BiosanaProcess Pte. Ltd. Singapore Republic of Singapore
  • Sartorius Stedim Netherlands B.V. Rotterdam The Netherlands
  • BiosanaPharma Leiden The Netherlands
Corresponding author
  • Pennings, Maarten
  • Ng, Say Kong
Venue
Biotechnology Journal
Publisher
Wiley
Published
2024-07
Volume
19
Issue
7
Pages
e2400092-e2400092
ISSN
  • 1860-6768 (ISSN-L)
  • 1860-7314
OpenAlex
W4400572166
Cited by
9
References
32
Citations by year
2026: 6 · 2025: 2 · 2024: 1
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Biotechnology Journal (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Agency for Science, Technology and Research (I1901E0047)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
CHO cell culture, monoclonal antibody production, biosimilars, cell-specific productivity, viable cell density, cell volume, growth arrest, feed rate control, bioreactor control
MeSH terms
Animals, Antibodies, Monoclonal, Cell Count, Cell Survival, Cricetulus, Perfusion, CHO Cells, Biomass, Cell Culture Techniques, Bioreactors, Cell Proliferation, Biosimilar Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.